Meropenem/vaborbactam
combination drug
Meropenem/vaborbactam, sold under the brand name Vabomere among others, is a combination medication used to treat complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia. It contains meropenem, a beta-lactam antibiotic; and vaborbactam, a beta-lactamase inhibitor. It is given by injection into a vein.
Common side effects include headache, inflammation at the site of injection, nausea, diarrhea, liver inflammation, and low blood potassium. Severe side effects may include anaphylaxis, seizures, and Clostridioides difficile-associated diarrhea. It is unclear if use during pregnancy is safe. Meropenem works by blocking the construction of the bacterial cell wall while vaborbactam blocks the breakdown of meropenem by some beta-lactamases.
The combination was approved for medical use in the United States in 2017, in the European Union in 2018, and in Canada in December 2024. It is on the World Health Organization's List of Essential Medicines.
Medical uses
It is used to treat complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia.
“Meropenem/vaborbactam” enters the record as combination drug. Crown Archives preserves that source wording while asking what Meropenem, vaborbactam and combination can confirm, complicate or overturn.
Why this record matters
“Meropenem/vaborbactam” is worth following because a concise public description often conceals a longer documentary argument. Here, Meropenem, vaborbactam and combination provides the most credible route into that argument.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Jun 4, 2026. The linked authority identifier is Q48566733. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2017, 2018 and 2024.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Meropenem/vaborbactam”, its source revision and the description used here.
- Expand the search: follow Meropenem/vaborbactam primary sources, Meropenem/vaborbactam archive and Meropenem research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Meropenem/vaborbactam”?
- What terminology or title could unlock a more precise catalogue search?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Meropenem/vaborbactam” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.